Therapeutic Advances in Hematology

Therapeutic Advances in Hematology delivers the highest quality peer-reviewed open access original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of blood disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in hematology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of hematology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies - all phases. Letters to the Editor and Case Reports will also be considered. Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.